Merck (MRK): Sen. John P Ricketts disclosed a sale $50K–$100K

$50,001–$100,000

Reported range · official band, not an exact amount

29 days

Disclosure lag

Traded

Sep 21, 2023

Disclosed

Oct 20, 2023

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 30, 2017CongressDisclosed sale of MRK — reported range $1,001 - $15,000
2. Jul 2, 2020CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
3. Mar 10, 2021CongressDisclosed sale of MRK — reported range $15,001 - $50,000
4. Jun 28, 2023CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
5. Jul 12, 2023CongressDisclosed sale of MRK — reported range $1,001 - $15,000
6. Jul 14, 2023CongressDisclosed sale of MRK — reported range $1,001 - $15,000
7. Aug 2, 2023CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
8. Sep 6, 2023CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
9. Sep 8, 2023CongressDisclosed sale of MRK — reported range $1,001 - $15,000
10. Sep 11, 2023CongressDisclosed partial sale of MRK — reported range $15,001 - $50,000
11. Sep 13, 2023CongressDisclosed sale of MRK — reported range $1,001 - $15,000
12. Sep 21, 2023 · this disclosureCongressDisclosed sale of MRK — reported range $50,001 - $100,000

What came next

1. Sep 26, 2023CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
2. Oct 12, 2023FDAFDA drug approval: Keytruda
3. Oct 16, 2023FDAFDA drug approval: Keytruda
4. Oct 16, 2023CongressDisclosed sale of MRK — reported range $1,001 - $15,000
5. Oct 23, 2023FDAFDA drug approval: Keytruda
6. Oct 24, 2023CongressDisclosed sale of MRK — reported range $1,001 - $15,000
7. Oct 31, 2023FDAFDA drug approval: Keytruda
8. Oct 31, 2023FDAFDA drug approval: Keytruda
9. Nov 7, 2023FDAFDA drug approval: Keytruda
10. Nov 16, 2023FDAFDA drug approval: Keytruda
11. Dec 14, 2023FDAFDA drug approval: Welireg
12. Dec 15, 2023FDAFDA drug approval: Keytruda
13. Dec 15, 2023FDAFDA drug approval: Keytruda
14. Jan 12, 2024FDAFDA drug approval: Keytruda

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Sen. John P Ricketts

• Senate eFD periodic transaction report at Yum! Brands (YUM)Oct 20, 2023
• Senate eFD periodic transaction report at Western Alliance Bancorporation (WAL)Oct 20, 2023
• Senate eFD periodic transaction report at Verizon (VZ)Oct 20, 2023
• Senate eFD periodic transaction report at Union Pacific Corporation (UNP)Oct 20, 2023
• Senate eFD periodic transaction report at UnitedHealth (UNH)Oct 20, 2023

The full history of Sen. John P Ricketts is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Merck

• SEC Form 144Nov 12, 2026
• SEC Form 144Nov 2, 2026
• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 24, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026

Everything OQRO holds on this company is on its MRK page.